Clinical Trial Update: Using Induced-Pluripotent Stem Cells to Model Cancer Therapy-Related Adverse Events

View source ↗

Summary

This update describes Mayo Clinic's study using patient-derived induced pluripotent stem cells to model adverse events associated with cancer therapies.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Malignancies
• Solid Tumors

Snippet

Sponsor: Mayo Clinic | Conditions: Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm | Status: RECRUITING